Benefits and Harms of COVID-19 Vaccines in Cardiovascular Disease: A Comprehensive Review
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Patients with a history of cardiovascular disease (CVD) who contract coronavirus disease 2019 (COVID-19) tend to have a worse prognosis and more severe cardiovascular side effects. COVID-19 vaccines, which are intended to prevent COVID-19, may also potentially reduce the severity and complications (including cardiovascular sequelae) of COVID-19, especially in patients with a history of CVD. However, there have also been reports of cardiovascular side effects from COVID-19 vaccines of various brands and types. The purpose of this study is to review the benefits and harms of COVID-19 vaccines in relation to CVD. In this thorough review of the most current evidence on the benefits and harms of COVID-19 vaccines, we present information about the characteristics of cardiovascular complications. Most of the evidence focuses on myocarditis or pericarditis, which are most strongly associated with mRNA vaccines and predominantly occur in young males within days of receiving the second dose. Meanwhile, post-vaccination myocardial infarction is more common in older males, and the first dose of adenoviral vector vaccines appears to play a greater role in this complication. This information may guide us in formulating alternative options and implementing targeted surveillance. Gaining more knowledge about the potential benefits and harms of COVID-19 vaccines will improve our ability to make informed decisions and judgments about the balance of these factors.
Abstract
Patients with a history of cardiovascular disease (CVD) who contract coronavirus disease 2019 (COVID-19) tend to have a worse prognosis and more severe cardiovascular side effects. COVID-19 vaccines, which are intended to prevent COVID-19, may also potentially reduce the severity and complications (including cardiovascular sequelae) of COVID-19, especially in patients with a history of CVD. However, there have also been reports of cardiovascular side effects from COVID-19 vaccines of various brands and types. The purpose of this study is to review the benefits and harms of COVID-19 vaccines in relation to CVD. In this thorough review of the most current evidence on the benefits and harms of COVID-19 vaccines, we present information about the characteristics of cardiovascular complications. Most of the evidence focuses on myocarditis or pericarditis, which are most strongly associated with mRNA vaccines and predominantly occur in young males within days of receiving the second dose. Meanwhile, post-vaccination myocardial infarction is more common in older males, and the first dose of adenoviral vector vaccines appears to play a greater role in this complication. This information may guide us in formulating alternative options and implementing targeted surveillance. Gaining more knowledge about the potential benefits and harms of COVID-19 vaccines will improve our ability to make informed decisions and judgments about the balance of these factors.
참고문헌 (40)
- Driggin E, "ACC health policy statement on cardiovascular disease considerations for covid-19 vaccine prioritization : a report of the American College of Cardiology Solution Set Oversight Committee", J Am Coll Cardiol, 77, pp.1938~1948 (2021)
- Arif Y, "Relation of 10-year ascvd risk score with severe COVID-19 outcomes", J Am Coll Cardiol, 79, pp.1848~ (2022)
- Abate SM, "Global burden of acute myocardial injury associated with COVID-19 : a systematic review, meta-analysis, and meta-regression", Ann Med Surg(Lond), 68, pp.102594~ (2021)
- Myers KD, "COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD", Am J Prev Cardiol, 7, pp.100197~ (2021)
- Beyerstedt S, "COVID-19 : angiotensin-converting enzyme 2(ACE2)expression and tissue susceptibility to SARS-CoV-2 infection", Eur J Clin Microbiol Infect Dis, 40, pp.905~919 (2021)
- Varga Z, "Endothelial cell infection and endotheliitis in COVID-19", Lancet, 395, pp.1417~1418 (2020)
- Atri D, "COVID-19 for the cardiologist : basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies", JACC Basic Transl Sci, 5, pp.518~536 (2020)
- Vuorio A, "Familial hypercholesterolaemia and COVID-19 : a two-hit scenario for endothelial dysfunction amenable to treatment", Atherosclerosis, 320, pp.53~60 (2021)
- Au WY, "Effectiveness of heterologous and homologous covid-19 vaccine regimens : living systematic review with network meta-analysis", BMJ, 377, pp.e069989~ (2022)
- Zou Y, "The vaccine efficacy against the SARS-CoV-2 omicron : a systemic review and meta-analysis", Front Public Health, 10, pp.940956~ (2022)
- Tseng HF, "Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants", Nat Med, 28, pp.1063~1071 (2022)
- Ho JS, "A review of COVID-19 vaccination and the reported cardiac manifestations", Singapore Med J (2021)
- Liu R, "Cardiovascular complications of COVID-19 vaccines", Front Cardiovasc Med, 9, pp.840929~ (2022)
- Özdemir İH, "Type 1 Kounis syndrome induced by inactivated SARS-COV-2 vaccine", J Emerg Med, 61, pp.e71~e76 (2021)
- "Vaccine Adverse Event Reporting System (VAERS) 1990–12/30/2022, CDC WONDER on-line database" (2023)[URL]
- Su WJ, "Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA vaccination-a nationwide study", J Microbiol Immunol Infect (2023)[DOI]
- Sadoff J, "Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19", N Engl J Med, 384, pp.2187~2201 (2021)
- Chang Y, "Cardiovascular safety of COVID-19 vaccines in real-world studies : a systematic review and meta-analysis", Expert Rev Vaccines, 22, pp.25~34 (2023)
- Pillay J, "Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination : living evidence syntheses and review", BMJ, 378, pp.e069445~ (2022)
- Larson KF, "Myocarditis after BNT162b2 and mRNA-1273 vaccination", Circulation, 144, pp.506~508 (2021)
- Mansanguan S, "Cardiovascular manifestation of the BNT162b2 mRNA COVID-19 vaccine in adolescents", Trop Med Infect Dis, 7, pp.196~ (2022)
- Le Vu S, "Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines", Nat Commun, 13, pp.3633~ (2022)
- Patone M, "Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection", Nat Med, 28, pp.410~422 (2022)
- Heymans S, "Myocarditis after COVID-19 mRNA vaccination : clinical observations and potential mechanisms", Nat Rev Cardiol, 19, pp.75~77 (2022)
- Freise NF, "Acute cardiac side effects after COVID-19 mRNA vaccination : a case series", Eur J Med Res, 27, pp.80~ (2022)
- Sun CL, "Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave", Sci Rep, 12, pp.6978~ (2022)
- Zafar U, "Link between COVID-19 vaccines and myocardial infarction", World J Clin Cases, 10, pp.10109~10119 (2022)
- Botton J, "Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France", Ann Intern Med, 175, pp.1250~1257 (2022)
- Aye YN, "Acute myocardial infarction and myocarditis following COVID-19 vaccination", QJM, 116, pp.279~283 (2023)
- Kim YE, "Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection", JAMA, 328, pp.887~889 (2022)
- Baronti A, "Myocardial infarction following COVID-19 vaccine administration : Post Hoc, Ergo Propter Hoc?", Viruses, 14, pp.1644~ (2022)
- Kumar A, "Atrial fibrillation after vaccination for COVID-19 : analysis of the vaccine adverse event reporting system", J Interv Card Electrophysiol, 65, pp.1~2 (2022)
- Sangpornsuk N, "Arrhythmias after SARS-CoV-2 vaccination in patients with a cardiac implantable electronic device : a multicenter study", Biomedicines, 10, pp.2838~ (2022)
- Bozkurt B, "Myocarditis with COVID-19 mRNA vaccines", Circulation, 144, pp.471~484 (2021)
- Ye X, "Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease", Cardiovasc Res, 118, pp.2329~2338 (2022)
- Raxwal B, "Comparison of SARS-COVID 2-vaccine in patients with cardiovascular disease", J Am Coll Cardiol, 81, pp.1802~ (2023)
- Xie Y, "Long-term cardiovascular outcomes of COVID-19", Nat Med, 28, pp.583~590 (2022)
- Antonelli M, "Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app : a prospective, community-based, nested, case-control study", Lancet Infect Dis, 22, pp.43~55 (2022)
- Ayoubkhani D, "Trajectory of long covid symptoms after covid-19 vaccination : community based cohort study", BMJ, 377, pp.e069676~ (2022)
- Azzolini E, "Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers", JAMA, 328, pp.676~678 (2022)